What alternative basal insulin can be used for a patient with type 2 diabetes mellitus who is currently taking insulin degludec 10 units subcutaneously once daily, given that insurance does not cover insulin degludec?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Alternative Basal Insulin for Insulin Degludec

NPH insulin or insulin glargine U-100 are the most appropriate alternatives to insulin degludec when insurance coverage is denied, with NPH being the most cost-effective option and insulin glargine U-100 offering a better safety profile with reduced nocturnal hypoglycemia risk. 1

Recommended Alternatives in Order of Preference

First-Line Alternative: Insulin Glargine U-100

  • Start with 10 units subcutaneously once daily (same dose as current degludec regimen) 1
  • Administer at bedtime or same time each day
  • Long-acting basal analog with proven efficacy comparable to degludec 2, 3
  • Lower risk of nocturnal and level 2 hypoglycemia compared to NPH insulin 2
  • Non-inferior glycemic control to degludec in clinical trials 3

Second-Line Alternative: NPH Insulin

  • Start with 10 units subcutaneously at bedtime 1
  • Most cost-effective basal insulin option
  • Higher risk of hypoglycemia and nocturnal hypoglycemia compared to analogs 1, 2
  • Requires resuspension before injection (roll vial gently, do not shake)
  • May need twice-daily dosing if glycemic control inadequate 1

Third-Line Alternative: Insulin Detemir

  • Start with 10 units subcutaneously once daily
  • May require twice-daily dosing (approximately 33% of patients) 3
  • Similar efficacy to glargine U-100 2

Titration Protocol (Same for All Alternatives)

Follow this evidence-based algorithm: 1

  • Set fasting plasma glucose (FPG) goal based on individualized targets
  • Increase dose by 2 units every 3 days until FPG goal achieved without hypoglycemia
  • For hypoglycemia: determine cause; if no clear reason, reduce dose by 10-20% 1
  • Reassess adequacy at every visit (every 3-6 months) 1

Critical Considerations

Cost and Access

  • NPH insulin is significantly less expensive than basal analogs but requires more careful monitoring 2
  • Insulin glargine U-100 may have generic or biosimilar options available
  • Check formulary coverage before prescribing 2

Safety Profile Differences

  • Glargine U-100 and detemir have lower hypoglycemia risk than NPH 2, 4
  • NPH has peak activity 4-6 hours post-injection, increasing between-meal and nocturnal hypoglycemia risk 4
  • All alternatives have higher day-to-day glucose variability compared to degludec 4

When to Avoid NPH

  • Patients with history of severe or nocturnal hypoglycemia
  • Patients with hypoglycemia unawareness
  • Elderly patients at high fall risk
  • Patients with erratic meal schedules

Monitoring Requirements

Essential monitoring after switching: 1

  • Check fasting blood glucose daily during titration
  • Assess for hypoglycemia symptoms, especially nocturnal
  • Prescribe glucagon for emergent hypoglycemia 1
  • Monitor HbA1c every 3 months
  • Evaluate for overbasalization signs: basal dose >0.5 units/kg, high bedtime-to-morning glucose differential 2

Common Pitfalls to Avoid

  • Do not assume unit-to-unit conversion: While starting at same dose (10 units) is reasonable, individual titration is required 5
  • Do not use NPH without proper patient education on resuspension technique and timing with meals 4
  • Avoid therapeutic inertia: Reassess and adjust every 3-6 months 1
  • Do not overlook hypoglycemia risk increase when switching from degludec to shorter-acting insulins 2, 4

References

Related Questions

What are the equivalent alternatives to insulin degludec (Tresiba) and how should the dose be converted when switching to other basal insulins?
In an elderly patient with type 2 diabetes, which basal insulin—insulin glargine or NPH insulin (Novolin N)—provides better glucose control?
A patient on insulin U‑500 24 units twice daily (total 120 units per day) with HbA1c 8.9% wants to switch to insulin degludec (Tresiba) U‑200; how many pens should be prescribed for a 30‑day supply?
Can the patient be treated with Tresiba (insulin degludec), Victoza (liraglutide), and NovoRapid (insulin aspart) sliding‑scale?
Can I combine Imeglyn (insulin degludec) with sulfonylureas?
What are the possible causes of brief (~20‑second) episodes of jumbled or distorted vision in a 68‑year‑old woman?
How can I differentiate tuberculous cervical lymphadenitis (scrofula) from acute mumps parotitis in a patient presenting with a cervical mass?
Is there a cure for autoimmune autonomic ganglionopathy?
In a child with normal thyroid‑stimulating hormone (TSH) and free thyroxine (free T4) but suspected hypothyroidism due to obesity, short stature, excessive sleepiness, and enuresis, what additional investigations should be performed to rule out hypothyroidism?
In a 68‑year‑old woman presenting with vertical diplopia described as one eye appearing lower and the other higher, what is the most likely cause and what urgent work‑up and initial management should be undertaken?
What is the appropriate evaluation and management for severe hypercalcemia (serum calcium 14.2 mg/dL) in an elderly male?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.